FrancophonIA/ELRC3.0 huggingface dataset:
English: QUALITATIVE AND QUANTITATIVE COMPOSITION One 1,000 mL bag contains 25 g of L-arginine hydrochloride and 25 g of L-lysine hydrochloride.
Maltese: U KWANTITATTIVA Borża waħda ta' 1,000 mL fiha 25 g ta' L-arginine hydrochloride u 25 g ta' L-lysine hydrochloride.
English: B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Maltese: Prodott mediċinali li jingħata b'riċetta ristretta tat-tabib (ara Anness I: Sommarju tal-Karatteristiċi tal-Prodott, sezzjoni 4.2).
English: If you receive more LysaKare than you should LysaKare will be given in a controlled clinical setting and is provided as a single dose bag.
Maltese: LysaKare se tingħata f'ambjent kliniku kontrollat u hija pprovduta bħala borża ta' doża waħda.
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING Polyethylene polyamine/aluminium foil
Maltese: TAGĦRIF LI GĦANDU JIDHER FUQ IL-PAKKETT TA' BARRA Polyethylene polyamine/fojl tal-aluminju
English: Due to potential for clinical complications related to volume overload care should be taken with use of arginine and lysine in patients with severe heart failure defined as class III or class IV in the NYHA classification.
Maltese: Minħabba l-potenzjal ta' komplikazzjonijiet kliniċi relatati ma' volum eċċessiv, għandha tingħata attenzjoni meta arginine u lysine jintużaw f'pazjenti b'insuffiċjenza severa tal-qalb definita bħala talklassi
English: The overwrap is a moisture barrier.
Maltese: It-tgeżwir ta' barra huwa barriera kontra l-umdità.
English: - Keep this leaflet.
Maltese: ċerti tumuri.
English: PHARMACEUTICAL FORM AND CONTENTS Solution for infusion
Maltese: GĦAMLA FARMAĊEWTIKA U KONTENUT
English: Treatment with lutetium (177Lu) oxodotreotide is not recommended for patients with severe heart failure defined as class III or class IV in the NYHA classification therefore, the benefit risk for these patients will always need to be weighed carefully.
Maltese: Lu) oxodotreotide mhuwiex rakkomandat għal pazjenti b'insuffiċjenza severa tal-qalb definita bħala tal-klassi III jew tal-klassi IV fil-klassifikazzjoni NYHA, għalhekk dejjem għandhom jitqiesu l-benefiċċji u r-riskji għal dawn il-pazjenti.
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: {DD month YYYY}
Maltese: DATA TAL-EWWEL AWTORIZZAZZJONI/TIĠDID TAL-AWTORIZZAZZJONI Data tal-ewwel awtorizzazzjoni: {JJ xahar SSSS}
English: Each infusion bag contains 25 g of L-arginine hydrochloride and 25 g of L-lysine hydrochloride.
Maltese: Kull borża tal-infużjoni fiha 25 mL ta' L-arginine hydrochloride u 20 g ta' L-lysine hydrochloride.
English: Arginine and lysine undergo glomerular filtration and, via competition, interfere with renal resorption of lutetium (177Lu) oxodotreotide, reducing the radiation dose delivered to the kidney.
Maltese: Arginine u lysine jgħaddu minn filtrazzjoni glomerulari u, permezz tal-kompetizzjoni jinterferixxu mal-assorbiment mill-ġdid mill-kliewi ta' lutetium (
English: Transient elevations in plasma arginine and lysine are observed after intravenous administration, whereupon the highly water soluble amino acids are quickly distributed throughout tissues and body fluid.
Maltese: Żidiet temporanji f'arginine u lysine fil-plażma huma osservati wara l-għoti ġol-vini, fejn l-aċidi amminiċi li jinħallu ħafna fl-ilma jiġu distribwiti malajr permezz tat-tessuti u l-fluwidi tal-ġisem.
English: In case of severe symptomatic hyperkalaemia, discontinuation of LysaKare infusion should be considered, taking into consideration the risk-benefit of renal protection versus acute hyperkalaemia.
Maltese: Fil-każ ta' iperkalimja sintomatika severa, għandu jiġi kkunsidrat it-twaqqif tal-infużjoni ta' LysaKare, filwaqt li jitqiesu l-benefiċċji u r-riskji tal-protezzjoni tal-kliewi kontra iperkalimja akuta.
English: Serum potassium level increases are generally mild and transient.
Maltese: Iż-żidiet fillivelli ta' potassju fis-serum ġeneralment huma ħfief u temporanji.
English: Adverse drug reaction
Maltese: IL-PRODOTT MEDIĊINALI
English: In the event of over-hydration or solute overload, the elimination should be promoted by frequent micturition or by forced diuresis and frequent bladder voiding.
Maltese: Fil-każ ta' idratazzjoni żejda jew volum eċċessiv ta' soluti, għandha tiġi promossa l-eliminazzjoni permezz ta' żieda fil-frekwenza tal-awrina jew permezz ta' diuresi sfurzata u żvojtar frekwenti talbużżieqa tal-awrina.
English: Hyperkalaemia
Maltese: Indeboliment tal-kliewi
English: Due to the potential for clinical complications related to volume overload and an increase of potassium in blood associated with the use of LysaKare, this product should not be administered in patients with creatinine clearance <30 mL/min.
Maltese: Minħabba l-potenzjal għal komplikazzjonijiet kliniċi relatati ma' volum eċċessiv u żieda fil-potassju fid-demm assoċjati mal-użu ta' LysaKare, dan il-prodott m'għandux jingħata lil pazjenti bi tneħħija tal-kreatinina <30 mL/min.
English: There are very limited data on the safety profile of arginine and lysine solution for infusion without concomitant administration of PRRT, which also includes the use of anti-emetics as pre-medication and often the concomitant use of short acting somatostatin analogues.
Maltese: Hemm data limitata ħafna dwar il-profil ta' sigurtà ta' soluzzjoni għall-infużjoni ta' arginine u lysine mingħajr l-użu fl-istess ħin ta' PRRT, li jinkludi wkoll l-użu ta' mediċini kontra t-tqalligħ bħala medikazzjoni minn qabel u ħafna drabi l-użu fl-istess ħin ta' analogi ta' somatostatin li jaġixxu għal ħin qasir.
English: Arginine and lysine are naturally occurring amino acids that follow physiological pharmacokinetic steps and biochemical processes after infusion.
Maltese: Arginine u lysine huma aċidi amminiċi li jseħħu b'mod naturali li jsegwu passi farmakokinetiċi fiżjoloġiċi u proċessi bijokimiċi wara l-infużjoni.
English: Because feeling sick (nausea) and vomiting are commonly seen with amino acid infusions, you will be given medicines to prevent nausea and vomitting 30 minutes before the LysaKare infusion.
Maltese: Minħabba li d-dardir (nawsja) u r-rimettar huma osservati komunement b'infużjonijiet ta' aċidi amminiċi, inti se tingħata mediċini li jevitaw in-nawsja u r-rimettar 30 minuta qabel l-infużjoni ta' LysaKare.
English: PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING Polyvinyl chloride (PVC) infusion bag
Maltese: TAGĦRIF LI GĦANDU JIDHER FUQ IL-PAKKETT LI JMISS MAL-PRODOTT Borża tal-infużjoni tal-polyvinyl chloride (PVC)
English: There is no relevant use of this medicinal product in women of childbearing potential since lutetium (177Lu) oxodotreotide is contraindicated during established or suspected pregnancy or when pregnancy has not been excluded due to the risk associated with the ionizing radiation (see section 4.1).
Maltese: Lu) oxodotreotide huwa kontraindikat matul tqala stabbilita jew suspettata jew meta ttqala ma tistax tiġi eskluża minħabba r-riskju assoċjat mar-radjazzjoni jonizzanti (ara sezzjoni 4.1).
English: An increase of serum potassium levels may occur in patients receiving arginine and lysine.
Maltese: Żieda fil-livelli ta' potassju fis-serum tista' sseħħ f'pazjenti li jingħataw arginine u lysine.
English: LysaKare and lutetium (177Lu) oxodotreotide must be given through a separate infusion line.
Maltese: Lu) oxodotreotide sabiex tinkiseb l-aħjar protezzjoni tal-kliewi.
English: No pharmacokinetic data are available on the use of arginine and lysine at the same dose as LysaKare and for the same indication in paediatric patients.
Maltese: Ebda data farmakokinetika ma hija disponibbli dwar l-użu ta' arginine u lysine fl-istess doża bħal LysaKare u għall-istess indikazzjoni f'pazjenti pedjatriċi.
English: EMA/267580/2011 EMEA/H/C/000266
Maltese: EMEA/H/C/000266
English: In the larger of the two studies, the sensitivity of DaTSCAN was 97%.
Maltese: Fl-ikbar studju, is-sensittività ta' DaTSCAN kienet 97%.
English: Other information about DaTSCAN:
Maltese: Informazzjoni oħra dwar DaTSCAN:
English: In dementia, the sensitivity of DaTSCAN in distinguishing dementia caused by Lewy bodies from other types of dementia ranged from 75 to 80%.
Maltese: F'demenza, is-sensittività ta' DaTSCAN meta jiddistingwi demenza kkawżata minn korpi Lewy minn tipi oħrajn ta' demenza kienet bejn 75 u 80%.
English: In movement disorders, DaTSCAN has been studied in 254 adults in two main studies.
Maltese: F'disturbi ta' moviment, DaTSCAN ġie studjat f'254 adult f'żewġ studji prinċipali.
English: This document is a summary of the European public assessment report (EPAR) for DaTSCAN.
Maltese: Dan id-dokument huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal DaTSCAN.
English: The active substance in DaTSCAN, ioflupane (123I), is a radiopharmaceutical.
Maltese: Is-sustanza attiva f'DaTSCAN, ioflupane (123I), hija radjufarmaċewtiku.
English: This can be seen using a special imaging technique called single-photon-emission computed tomography (SPECT), which detects the radioactive iodine-123.
Maltese: Dan jidher bl-użu ta' teknika ta' immaġni speċjali msejħa tomografija kkalkulata bl-emissjoni unika ta' photon (SPECT) (single-photon-emission computed tomography), li ssib il-jodju-123 radjuattiv.
English: It contains a substance called ioflupane, which is labelled with 123I (iodine-123), a radioactive form of the chemical element iodine.
Maltese: Dan fih sustanza, ioflupane, li ġiet immarkata bi 123I (jodju-123), forma radjuattiva tal-element kimiku jodju.
English: This summary was last updated in 04-2011.
Maltese: Dan is-sommarju ġie aġġornat l-aħħar fi: 07-2010.
English: DaTSCAN is a solution for injection that contains the active substance ioflupane (123I).
Maltese: DaTSCAN hu soluzzjoni għall-injezzjoni li fiha s-sustanza attiva ioflupane (123I).
English: DaTSCAN is given by slow injection lasting no less than 15 to 20 seconds into an arm vein.
Maltese: DaTSCAN jingħata b'injezzjoni bil-mod li ddum mhux anqas minn 15 sa 20 sekonda f'vina fid-driegħ.
English: The European Commission granted a marketing authorisation valid throughout the European Union for DaTSCAN to GE Healthcare Limited on 27 July 2000.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq għal DaTSCAN valida fl-Unjoni Ewropea kollha lil GE Healthcare Limited fis-27 ta' Lulju 2000.
English: In the studies, images obtained in 45 healthy volunteers were compared with those obtained in 180 patients with Parkinson's disease or related diseases, and in 29 patients with essential tremor.
Maltese: Fl-istudji, l-immaġni miksubin f'54 voluntier b'saħħtu tqabblu ma' dawk miksubin f'180 pazjent bil-marda ta' Parkinson jew mard relatat, u f'29 pazjent b'rogħda essenzjali.
English: The risk caused by radioactivity is thought to be very low.
Maltese: Ir-riskju kkawżat minn radjuattività huwa maħsub li huwa baxx ħafna.
English: When DaTSCAN is injected, ioflupane (123I) is distributed through the body in the blood and accumulates in the striatum, where it attaches to the structures that transport dopamine.
Maltese: Meta jiġi injettat DaTSCAN, ioflupane (123I) jiġi distribwit madwar il-ġisem fid-demm u jakkumula flistriatum, fejn jeħel mal-istrutturi li jittrasportaw dopamine.
English: What is DaTSCAN?
Maltese: X'inhu DaTSCAN?
English: What is the risk associated with DaTSCAN?
Maltese: X'inhu r-riskju assoċjat ma' DaTSCAN?
English: In dementia, DaTSCAN has been studied in one main study involving 288 adults who had been diagnosed with dementia with Lewy bodies or Alzheimer's disease, or another form of dementia.
Maltese: F'demenza, DaTSCAN ġie studjat fi studju prinċipali li kien jinvolvi 288 adult li kienu dijanjostikati b'demenza b'korpi Lewy jew bil-marda ta' Alzheimeer, jew forma oħra ta' demenza.
English: Why has DaTSCAN been approved?
Maltese: Għaliex ġie approvat DaTSCAN?
English: How has DaTSCAN been studied?
Maltese: Kif ġie studjat DaTSCAN?
English: DaTSCAN is used to help distinguish between a type of dementia known as ‘dementia with Lewy bodies' and Alzheimer's disease.
Maltese: • DaTSCAN jintuża biex jgħin jiddistingwi bejn tip ta' demenza magħrufa bħala ‘demenza b'korpi Lewy' u l-marda ta' Alzheimer.
English: Ioflupane attaches specifically to structures on the surface of nerve cell endings in the striatum that are responsible for the transport of dopamine.
Maltese: Ioplupane jeħel speċifikament ma' strutturi fuq il-wiċċ mat-trufijiet taċ-ċelloli tan-nervituri fl-istriatum li huma responsabbli għat-trasport ta' dopamine.
English: In patients with Parkinson's disease and related diseases, and in patients with dementia with Lewy bodies, there is typically a loss of nerve cells in the striatum containing dopamine.
Maltese: F'pazjenti bil-marda ta' Parkinson u mard relatat, u f'pazjenti b'demenza b'korpi Lewy, hemm tipikament telf ta' ċelloli tan-nervituri fl-istriatum li fihom dopamine.
English: When receiving DaTSCAN, patients must also take another medicine, such as iodine tablets, to prevent their thyroid gland from taking up the iodine contained in DaTSCAN.
Maltese: Meta jkunu qed jieħdu DaTSCAN, ilpazjenti jridu jieħdu wkoll mediċina oħra, bħal pilloli jodju, sabiex jipprevjeni li l-glandola tirojde tagħhom tieħu l-jodju li fih DaTSCAN.
English: Resuscitation equipment should be available before DaTSCAN is given, in case the patient has an allergic reaction.
Maltese: Għandu jkun hemm disponibbli apparat ta' rianimazzjoni qabel ma jingħata DaTSCAN, f'każ li l-pazjent ikollu reazzjoni allerġika.
English: The most common side effect with DaTSCAN (seen in between 1 and 10 patients in 100) is headache.
Maltese: L-effetti sekondarji l-aktar komuni b'DaTSCAN (li jidhru b'bejn pazjent 1 u 10 minn kull 100) huma żieda fl-aptit, uġigħ ta' ras, formikazzjoni (sensazzjoni ta' xi ħaġa qed tiġri fuq jew taħt il-ġilda), u vertiġni (sensazzjoni ta' tidwir).
English: For the full list of all side effects reported with DaTSCAN, see the package leaflet.
Maltese: Għal-lista sħiħa tal-effetti sekondarji rrapportati b'DaTSCAN, ara l-fuljett ta' tagħrif.
English: The CHMP decided that DaTSCAN's benefits are greater than its risks and recommended that it be given marketing authorisation.
Maltese: Is-CHMP iddeċieda li l-benefiċċji ta' DaTSCAN huma akbar mir-riskji tiegħu u rrakkomanda li jingħata awtorizzazzjoni għat-tqegħid fis-suq.
English: (Invented) Name
Maltese: Numru ta' l-EU Isem (ivvintat)
English: EMA/464279/2015 EMEA/V/C/003942
Maltese: EMEA/V/C/003942
English: The full EPAR for Porcilis PCV ID can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
English: Porcilis PCV ID contains the active substance porcine circovirus (PCV2) ORF2 subunit antigen.
Maltese: Porcilis PCV ID fih is-sustanza attiva antiġen tas-sottounità ORF2 taċ-circovirus tal-qżieqeż (PCV2).
English: The European Commission granted a marketing authorisation valid throughout the EU for Porcilis PCV ID on 28 August 2015.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq valida fl-UE kollha għal Porcilis PCV ID fit-28 ta' Awwissu 2015.
English: Porcilis PCV ID is a veterinary vaccine against porcine circovirus type 2 (PCV2) infection in pigs.
Maltese: Porcilis PCV ID huwa vaċċin veterinarju kontra l-infezzjoni taċ-circovirus tal-qżieqeż ta' tip 2 (PCV2) filħnieżer.
English: This is a summary of the European public assessment report (EPAR) for Porcilis PCV ID.
Maltese: Dan huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal Porcilis PCV ID.
English: PCV2 is recognised as the primary cause of post-weaning multisystemic wasting syndrome (PMWS), but is also associated with a number of other conditions collectively known as porcine circovirus disease in Europe (PCVD) e.g porcine respiratory disease complex (PRDC), enteritis, reproductive disorders.
Maltese: PCV2 huwa rikonoxxut bħala l-kawża ewlenija tassindrome ta' tkissir multisistemiku wara l-fatma (PMWS), iżda huwa assoċjat ukoll ma' numru ta' kundizzjonijiet oħrajn magħrufa kollettivament bħala l-marda taċ-circovirus tal-qżieqeż fl-Ewropa (PCVD) eż. il-kumpless tal-mard respiratorju tal-qżieqeż (PRDC), enterite, disturbi fis-sistema riproduttiva.
English: Porcilis PCV ID contains the adjuvant light mineral oil and dl-α-tocopheryl acetate to enhance the immune response.
Maltese: Porcilis PCV ID fih l-aġġuvant żejt minerali ħafif u l-aċetat dl-α-tocopheryl biex itejjeb ir-rispons immunitarju.
English: Porcilis PCV ID is a vaccine.
Maltese: Porcilis PCV ID huwa vaċċin.
English: Porcine circovirus vaccine (inactivated)
Maltese: Vaċċin taċ-circovirus tal-qżieqeż (inattivat)
English: Porcilis PCV ID is an emulsion containing mineral oil.
Maltese: Porcilis PCV ID huwa emulsjoni li fih żejt minerali.
English: The vaccine contains small amounts of a protein from PCV2.
Maltese: Il-vaċċin fih ammonti żgħar ta' proteina minn PCV2.
English: The most common side effect with Porcilis PCV ID (seen in more than 1 in 10 pigs) is a short-lived local reaction with hard non-painful swellings up to 2 cm in diameter which disappear within about five weeks of vaccination.
Maltese: L-effetti sekondarji l-aktar komuni b'Porcilis PCV ID (li jistgħu jaffettwaw aktar minn 1 minn kull għaxart iħnieżer) huma reazzjoni qasira b'nefħiet ibsin mingħajr uġigħ b'dijametru massimu ta' 2 cm li jitilqu wara madwar ħames ġimgħat ta' tilqim.
English: Why is Porcilis PCV ID approved?
Maltese: Għaliex ġie approvat Porcilis PCV ID?
English: What are the risks associated with Porcilis PCV ID?
Maltese: X'inhuma r-riskji assoċjati ma' Porcilis PCV ID?
English: This will help reduce the PCV2 viraemia, virus load in the lungs and lymphoid tissue and virus shedding.
Maltese: Dan sejjer jgħin inaqqas il-viremija ta' PCV2, l-ammont ta' virus fil-pulmuni u t-tessuti limfatiki u t-tifrix tal-virus.
English: The vaccine is given to fattening pigs from three weeks of age as a single injection into the skin at the side of the neck, along the back or in the hind leg. Protection against PCV 2 starts two weeks after vaccination and lasts for 23 weeks after vaccination.
Maltese: L-istudji tal-laboratorju wrew li l-vaċċin kellu l-effett totali tiegħu kontra PCV2 fi żmien ġimagħtejn u dik il-protezzjoni damet sa 23 ġimgħa wara t-tilqima.
English: Porcilis PCV ID has also been investigated in three field studies involving pig farms where PCV2 infection was present.
Maltese: Porcilis PCV ID ġie investigat ukoll fi tliet studji tal-qasam li involvew irziezet tal-ħnieżer fej kienet preżenti l-infezzjoni ta' PCV2.
English: In the future, if the animals are exposed to the virus the immune system will be able to respond more quickly.
Maltese: Jekk fil-futur l-annimali jkunu esposti għall-virus, issistema immunitarja tkun kapaċi tirreaġixxi aktar malajr.
English: When Porcilis PCV ID is given to pigs, the animals' immune system recognises the virus protein as ‘foreign' and reacts by building up an active immune response.
Maltese: Meta ħanżir jingħata Porcilis PCV ID, is-sistema immunitarja tal-annimali tagħraf lill-proteina tal-virus bħala waħda ‘barranija' u tirreaġixxi billi tibni rispons immunitarju attiv.
English: The vaccine is used to reduce viraemia (presence of the virus in the blood), virus load in the lungs and lymphoid tissues and virus shedding.
Maltese: Il-vaċċin jintuża biex inaqqas il-viremija (preżenza tal-virus fid-demm), l-ammont ta' virus filpulmun u t-tessuti limfatiki u t-tixrid tal-virus.
English: How is Porcilis PCV ID used?
Maltese: Kif jaħdem Porcilis PCV ID?
English: See section 2, Do not take Efficib.
Maltese: Ara sezzjoni 2, Tiħux Efficib.
English: Analysis of the results for overweight patients treated with metformin after failure of diet alone showed: - a significant reduction of the absolute risk of any diabetes-related complication in the metformin group (29.8 events/1,000 patient-years) versus diet alone (43.3 events/1,000 patient-years), p=0.0023, and versus the combined sulphonylurea and insulin monotherapy groups (40.1 events/1,000 patient-years), p=0.0034 - a significant reduction of the absolute risk of any diabetes-related mortality: metformin 7.5 events/1,000 patient-years, diet alone 12.7 events/1,000 patient-years, p=0.017 - a significant reduction of the absolute risk of overall mortality: metformin 13.5 events/1,000 patient-years versus diet alone 20.6 events/1,000 patient-years, (p=0.011), and versus the combined sulphonylurea and insulin monotherapy groups 18.9 events/1,000 patient-years (p=0.021) - a significant reduction in the absolute risk of myocardial infarction: metformin 11 events/1,000 patient-years, diet alone 18 events/1,000 patient-years, (p=0.01).
Maltese: - tnaqqis sinifikanti fir-riskju assolut ta' kwalunkwe kumplikazzjoni relatata mad-dijabete filgrupp ta' metformin (29.8 episodju/1,000 pazjenti-snin) kontra dieta waħidha (43.3 episodju/1,000 pazjenti-snin), p=0.0023, u kontra l-gruppi ta' monoterapija ta' kumbinazzjoni ta' sulphonylurea u insulina (40.1 episodju/1,000 pazjenti-snin), p=0.0034 - tnaqqis sinifikanti fir-riskju assolut ta' kwalunkwe mortalità relatata mad-dijabete: metformin 7.5 episodji/1,000 pazjenti-snin, dieta waħidha 12.7-il episodju /1,000 pazjenti-snin, p=0.017 - tnaqqis sinifikanti fir-riskju assolut ta' mortalità totali: metformin 13.5-il episodju/1,000 pazjenti-snin kontra dieta waħidha 20.6 episodju/1,000 pazjenti-snin, (p=0.011), u kontra l-gruppi ta' monoterapija ta' kumbinazzjoni ta' sulphonylurea u insulina 18.9-il episodju/1,000 pazjenti-snin (p=0.021) - tnaqqis sinifikanti fir-riskju assolut ta' infart majokardjali: metformin 11-il episodju/1,000 pazjenti-snin, dieta waħidha 18-il episodju/1,000 pazjenti-snin, (p=0.01).
English: Other medicines and Efficib
Maltese: Mediċini oħra u Efficib
English: In addition, the film coating contains: poly(vinyl alcohol), macrogol 3350, talc (E553b), titanium dioxide (E171), iron oxide red (E172), and iron oxide black (E172).
Maltese: Barra minn hekk, il-kisja tarrita fiha: polyvinyl alcohol, macrogol 3350, talc (E553b), titanium dioxide (E171), iron oxide red (E172), u iron oxide black (E172).
English: Efficib combines two antihyperglycaemic medicinal products with complementary mechanisms of action to improve glycaemic control in patients with type 2 diabetes: sitagliptin phosphate, a dipeptidyl peptidase 4 (DPP-4) inhibitor, and metformin hydrochloride, a member of the biguanide class.
Maltese: Efficib jikkumbina żewġ prodotti mediċinali kontra l-ipergliċemija b'mekkaniżmi ta' azzjoni kumplimentari biex jitjieb il-kontroll gliċemiku f'pazjenti b'dijabete tip 2: sitagliptin phosphate, li hu impeditur dipeptidyl peptidase 4 (DPP-4), u metformin hydrochloride, li hu membru tal-klassi biguanide.
English: Efficib contains two different medicines called sitagliptin and metformin.
Maltese: Efficib fih żewġ mediċini differenti msejħin sitagliptin u metformin.
English: EU/1/08/457/001 14 film-coated tablets EU/1/08/457/002 28 film-coated tablets EU/1/08/457/003 56 film-coated tablets EU/1/08/457/019 60 film-coated tablets EU/1/08/457/004 112 film-coated tablets EU/1/08/457/005 168 film-coated tablets EU/1/08/457/020 180 film-coated tablets EU/1/08/457/006 196 film-coated tablets EU/1/08/457/007 50 x 1 film-coated tablets EU/1/08/457/015 196 (2 x 98) film-coated tablets EU/1/08/457/017 168 (2 x 84) film-coated tablets
Maltese: EU/1/08/457/019 60 pillola miksija b'rita EU/1/08/457/004 112-il pillola miksija b'rita EU/1/08/457/005 168 pillola miksija b'rita EU/1/08/457/020 180 pillola miksija b'rita EU/1/08/457/006 196 pillola miksija b'rita EU/1/08/457/007 50 x 1 pillola miksija b'rita EU/1/08/457/015 196 (2 pakketti ta' 98) pillola miksija b'rita EU/1/08/457/017 168 (2 pakketti ta' 84) pillola miksija b'rita